Swiss National Bank increased its stake in shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) by 10.2% during the second quarter, Holdings Channel reports. The firm owned 15,100 shares of the specialty pharmaceutical company’s stock after buying an additional 1,400 shares during the period. Swiss National Bank owned about 0.10% of Eagle Pharmaceuticals worth $586,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in EGRX. LaSalle Street Capital Management LLC bought a new stake in shares of Eagle Pharmaceuticals during the second quarter valued at about $304,000. Columbus Circle Investors bought a new stake in shares of Eagle Pharmaceuticals during the second quarter valued at about $306,000. Royal Bank of Canada raised its stake in shares of Eagle Pharmaceuticals by 64.3% in the first quarter. Royal Bank of Canada now owns 11,934 shares of the specialty pharmaceutical company’s stock valued at $484,000 after buying an additional 4,670 shares during the period. California State Teachers Retirement System raised its stake in shares of Eagle Pharmaceuticals by 2.1% in the second quarter. California State Teachers Retirement System now owns 18,565 shares of the specialty pharmaceutical company’s stock valued at $720,000 after buying an additional 385 shares during the period. Finally, Alps Advisors Inc. bought a new stake in shares of Eagle Pharmaceuticals during the second quarter valued at about $852,000.
Shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) traded down 0.77% on Friday, hitting $63.07. 62,398 shares of the stock were exchanged. Eagle Pharmaceuticals Inc. has a 52-week low of $33.02 and a 52-week high of $102.48. The company has a 50 day moving average of $63.99 and a 200 day moving average of $49.38. The company has a market cap of $986.16 million, a price-to-earnings ratio of 323.44 and a beta of 1.16.
Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.80 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.09. The company had revenue of $40.90 million for the quarter, compared to analysts’ expectations of $43.55 million. Eagle Pharmaceuticals had a net margin of 3.45% and a return on equity of 3.44%. Eagle Pharmaceuticals’s revenue for the quarter was up 581.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.53) earnings per share. Equities research analysts forecast that Eagle Pharmaceuticals Inc. will post $3.21 earnings per share for the current year.
Several equities research analysts recently commented on the stock. RBC Capital Markets reiterated an “outperform” rating and set a $80.00 target price (up from $78.00) on shares of Eagle Pharmaceuticals in a research report on Thursday, September 22nd. Zacks Investment Research upgraded shares of Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 20th. Mizuho lifted their target price on shares of Eagle Pharmaceuticals from $47.00 to $65.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 16th. Finally, TheStreet upgraded shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 9th. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $90.24.
In related news, major shareholder Proquest Investments Iv, L.P. sold 24,949 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $60.77, for a total value of $1,516,150.73. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 18.80% of the stock is currently owned by corporate insiders.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).